October 19, 2012

WellTransitions could be couched as another way in which Walgreens is striving to create solutions that lower the cost of overall health care outside of the physical retail pharmacy space, because it is. WellTransitions also could be characterized as a program that will routinely chip away at the $25 billion associated with hospital re-admissions by having more prescriptions filled at the pharmacy counter, because it does. But the real impact of this news? The real clincher? Hospitals need retail pharmacy if they're going to focus on reducing re-admissions, eliminating unnecessary healthcare costs and avoiding those penalties.

And that's the direction Walgreens is headed. Most recently, the company added managed care vet Brad Fluegel as chief strategy officer, adding another talented expert to Walgreens chief Greg Wasson’s dream team, which he has described as the “perfect blend of internal, long-term talent” and “external expertise and talents” that is helping to accelerate a massive transformation in its business. (For exclusive coverage of all Walgreens' efforts, click here for the Sept. 24 DSN special report.)

October 18, 2012

Walgreens on Thursday announced the appointment of Brad Fluegel as SVP and chief strategy officer.

September 18, 2012

Walgreens on Tuesday announced several new senior management roles, including an expanded role for CFO Wade Miquelon and the appointment of current SVP and chief strategy officer Robert Zimmerman as the lead executive responsible for the Walgreens-Alliance Boots' "synergy team."